CellNovo

CellNovo is a medical device company based in Paris and London that develops and markets a mobile diabetes management system featuring a connected insulin micro-patch pump, an activity monitor, and a cellular-enabled touchscreen handset. The compact, tubeless hardware optimizes insulin injections and enables real-time remote data transmission for Type 1 diabetes patients and other insulin-dependent individuals across the United Kingdom and several European countries. Prior to entering the public markets, the enterprise secured significant private capital to develop its technology, including distinct venture funding rounds of $43 million and $48 million. The organization is backed by notable institutional investors such as Advent Life Sciences and Air Liquide, and it subsequently raised €31.6 million during its 2015 initial public offering on Euronext Paris, achieving a market capitalization of €113.6 million. CellNovo was founded in 2002 by Ian Shapley.